Introduction
MHC class I (MHC-I) molecules present cell surface self/foreign peptides to cytotoxic T lymphocytes and are crucial in the immune response (1) . During cancer initiation and progression, MHC-I molecules present tumor-associated antigens that are recognized as foreign antigens, promoting lysis of tumor cells by cytotoxic T lymphocytes (2) (3) (4) . The involvement of MHC-I expression in the immunogenicity of tumor cells is well documented (5) (6) (7) (8) (9) . Seven altered human leukocite antigen (HLA) class I phenotypes have been described in human tumor cells, and multiple molecular mechanisms have been implicated in these HLA defects (10, 11) .
The loss of one MHC-I haplotype can often be followed by total loss of MHC-I expression due to other molecular mechanisms, e.g. antigen-processing machinery (APM) component downregulation (12) (13) (14) . Accordingly, the initial loss of MHC-I molecules may allow cells to evade the initial immune response, leading to the emergence of tumor escape variants (15, 16) that the immune system might not subsequently recognize during the so-called 'immunoblindness phase' of tumor progression (17) . During this phase, the immune system loses control over tumor cells, which progress and invade and colonize tissues, producing metastases (18) . There may also be HLA class I expression losses unrelated to immune escape. Our group reported that loss of HLA class I surface expression on human melanoma cells grown in immunodeficient mice with no autologous immune response gave rise to more oncogenic tumor cells in vivo (17, 19) , although a direct causative relationship was not established. The biological significance of these new HLA losses has yet to be elucidated.
The present investigation describes two successive stages of HLA loss in melanoma cells: (i) loss of one HLA class I haplotype during tumor progression in a patient and (ii) transcriptional downregulation of APM components and HLA class I heavy chain genes during tumor growth in immunodeficient mice, leading to total loss of HLA class I cell surface expression. HLA gene transfection experiments demonstrated that the first HLA class I alteration (loss of one haplotype) permitted tumor cell escape from the patient's immune system. Importantly, both stages of HLA class I alterations increased the in vivo intrinsic oncogenic capacity and in vitro proliferation rate of the cells and augmented their migratory and invasive potential.
Materials and methods

Cell lines and reagents
The Ando-2 melanoma cell line, from a patient with malignant melanoma, was kindly provided by Dr P. Coulie [Université Catholique de Louvain (UCL), Brussels, Belgium]. Ando-Nude melanoma cell lines were established in vitro after growth in nude mice (19) . Cell lines were maintained in ISCOVE culture medium (Gibco, Paisley, UK) supplemented with 10% fetal calf serum (Life Technologies, Milan, Italy) and antibiotics. Epstein-Barr virus (EBV)-transformed autologous B lymphocytes (Ando-EBV) and K-562 cell lines were cultured in RPMI medium supplemented as described above. Mixed lymphocyte-tumor cell culture experiments were performed in ISCOVE medium as described above but with human serum replacing fetal calf serum. All cell lines were characterized by PCR assay using short tandem repeat markers, and they were also regularly tested for MHC-I genotype and surface expression.
Cloning of HLA-A
Ã 0201 complementary DNA and transfection into autologous Ando-2 melanoma cells HLA-A Ã 0201 complementary DNA was cloned from Ando-EBV cells. The PCR product was purified and cloned using the pcDNA3.1/D Expression kit (Invitrogen, Paisley, UK), and the plasmid obtained was designated pcDNA-A2. The empty vector was used as control vector (pcDNA-control). Next, Ando-2 melanoma cells (1 Â 10 6 /ml) were cultured in six-well plates at 37°C in 5% CO 2 atmosphere and then transfected with 1 lg of digested pcDNA-A2 plasmid or pcDNA-control, using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. The transfected melanoma cells were designated Ando-TA2 and Ando-Tmock, respectively. See Supplementary Information, available at Carcinogenesis Online, for additional details.
Analysis of surface HLA expression Surface HLA class I expression on cultured cells was determined by indirect immunofluorescence using the appropriate anti-class-I monoclonal antibody and fluorescein isothiocyanate-labeled rabbit antimouse Ig (Fab2) fragments (Sigma, St Louis, MO). A more detailed description is given in the Supplementary Information, available at Carcinogenesis Online.
Analysis of antitumor cytotoxic T lymphocytes with mixed lymphocyte-tumor cell cultures
Mixed lymphocyte-tumor cell cultures were set up to estimate the blood frequency of cytotoxic T lymphocyte precursors (CTLps), specifically directed against the tumor. Blood CD8 þ lymphocytes were purified from thawed peripheral blood mononuclear cells by magnetic beads (Miltenyi Biotec, GmbH, Germany). A previously reported assay protocol (20) In vitro proliferation test The proliferation rate was determined by using the non-toxic colorimetricbased assay Alamar Blue (Biosource, Camarillo, CA) as described previously (21) . See Supplementary Information, available at Carcinogenesis Online, for additional details.
Cell cycle analysis Cells were incubated with 1 mM bromodeoxyuridine for 1 h at 37°C and processed using the fluorescein isothiocyanate bromodeoxyuridine flow kit (BD Biosciences, San Diego, CA) following the manufacturer's instructions. See Supplementary Information, available at Carcinogenesis Online, for additional details.
Gene expression profiling on Agilent microarrays and reverse transcription and quantitative real-time reverse transcription-PCR The Agilent Whole Human Genome Oligo Microarray (G4112A) (Agilent Technologies, Santa Clara, CA) was used. Five micrograms of total RNA of each melanoma cell line were amplified, carrying out probe labeling and hybridization in accordance with the manufacturer's instructions. Fluorescence array images for Cy3 and Cy5 were scanned with an Agilent fluorescent scanner, and Feature Extraction software was used to grid, extract image intensities and normalize data.
The messenger RNA isolation kit (Miltenyi Biotec) was used to extract messenger RNA from tumor cell lines under baseline conditions. Real-time quantitative PCR analyses (for genes listed in Table I ) were performed in the 7500 Fast System (Applied Biosystems), using Gliceraldehyde-3-phospate dehidrogenase and TATA-binding protein genes as housekeeping genes (TaqMan gene expression assays from Applied Biosystems). See further description in the Supplementary Information, available at Carcinogenesis Online.
Migration and invasion assays
Migration and invasion assays were performed using Boyden Chambers containing polycarbonate filters with 8 lm pore size (Becton-Dickinson). Each assay was performed in duplicate and repeated at least three times. See Supplementary Information, available at Carcinogenesis Online, for additional details.
Statistical analysis
Data were expressed as mean ± SD. The paired Student's t-test was used to compare mean values. P 0.05 was considered significant. SPSS 16.0.2 (SPSS, Chicago, IL) was used for data analyses.
Results
MHC-I surface expression in Ando-2 tumor system
The Ando-2 melanoma cell line had a loss of heterozygosity in chromosome 6 and presented surface expression of only one HLA class I haplotype ( Figure 1 ). The lost HLA haplotype was HLA-A2, HLA-B13 and HLA-Cw6 (19) . Transfection of Ando-2 cells with plasmid pcDNA-A2 recovered expression of HLA-A2, one of the lost HLA alleles. Various clones with high surface expression of HLA-A2 allele from different transfection assays were selected and designated Ando-TA2 cells (Figure 1 ). Ando-2 melanoma cells transfected with the vector pcDNA-control, designated Ando-Tmock cells, showed practically identical surface HLA class I expression to that of Ando-2 cells (Figure 1 ). Ando-2 melanoma cells were injected in nude mice, obtaining Ando-Nude melanoma cell lines after local growth (19) . These cells had total loss of HLA class I expression ( Figure 1 ) due to the coordinated downregulation of several APM components (19) . Transfection with HLA-A2 gene did not recover the expression of these APM components, and Ando-Nude-transfected cells therefore had the same expression as Ando-Nude cells, i.e. total loss of HLA class I surface expression (data not shown). Ando-Nude-TA2 cells and their corresponding Ando-Nude-Tmock cells had total loss of HLA class I surface expression and showed the same results as for Ando-Nude cells in all assays performed in this study, as detailed below.
The Ando-2 tumor system comprises three melanoma cell lines (with the exception of the controls), Ando-2, Ando-TA2 and AndoNude, which derive from the same cell line but have different HLA class I surface expressions. At least three additional clones or batches (i.e. cells from different transfection assays for Ando-TA2 or AndoTmock cells lines, from different in vivo growth assays for AndoNude cells and from different culture passages for Ando-2 cells) were tested for surface HLA class I expression and practically identical results were obtained. 
Presence of specific CTLps against Ando-TA2 melanoma cells in the patient's blood
The presence of CTLps specifically recognizing Ando-TA2 cells was determined to test the possibility that Ando-2 melanoma cells were immunoselected in the patient after the loss of one HLA haplotype as escape mechanism. We performed mixed lymphocyte-tumor cell cultures to estimate the frequency in blood of CTLps directed specifically against the Ando-TA2 tumor cells, as described previously (20) . Purified CD8 blood T cells were stimulated with irradiated Ando-TA2 tumor cells in limiting dilution conditions with 375-3000 lymphocytes per microculture. After three weekly stimulations, the lytic activity of the microcultures was tested against the following cells: Ando-TA2, Ando-Tmock, Ando-2, autologous EBV-transformed B cells (Ando-EBV) and Natural Killer (NK) target K-562. Precise criteria and representative results are shown in Figure 2 . Out of 48 microcultures with 1500 lymphocytes, 5 were positive. Out of 48 microcultures with 375 lymphocytes, 1 was positive. Antitumor CTLps, which specifically recognize Ando-TA2 tumor cells, were present in the blood at a frequency of 6 Â 10 À5 , indicating the previous generation in this patient of an immune response against melanoma cells expressing the HLA-A2 molecule. These assays were repeated with at least three additional clones or batches of each cell line and the results obtained were always the same.
MHC-I expression determines in vivo local growth of melanoma cells in immunodeficient mice
We studied in vivo local growth in nude and SCID-Beige mice in order to analyze the in vivo tumorigenic potential of these melanoma cell lines in the absence of an autologous immune response. These immunodeficient mice were selected because Ando-Nude cells were obtained from them, and SCID-Beige mice are the usual choice for reconstitution assays with immune human cells. Three cell doses (1, 2.5 and 5 million) were injected in groups of 10 mice each and local growth was monitored. Ando-2 melanoma cells did not grow in the nude mice at doses of 1 or 2.5 million cells, showed a very low growth rate at a dose of 5 million cells and only reaching a maximum tumor diameter of 10 mm at day 60 ( Figure 3a) . The results for Ando-Tmock and Ando-2 melanoma cells were very similar (Figure 3c ). AndoNude cells grew at all cell doses used at a higher growth rate versus MHC-I molecules act as tumor suppressor genes B cells. No significant differences were found between the results for nude and SCID-Beige mice (data not shown). All the above in vivo local growth assays were repeated using other different clones or batches of each melanoma cell line, and the same results were always observed. Splenocytes were isolated from nude mice previously injected with Ando-2, Ando-Nude, Ando-TA2 or Ando-Tmock human melanoma cells to rule out the possibility that NK cells or residual T cells from nude mice recognize some of these human melanoma cell lines and alter their in vivo local growth. We performed assays on CTLps frequency, using the methods described above for the patient-derived T-CD8 þ cells but in this case, using cells from the spleen of nude mice previously injected with each of these human melanoma cell lines. These assays detected no presence of CTLps against these human melanoma cell lines in the nude mice. Other cytotoxic activities (e.g. NK cytotoxic activity) were studied, using splenocytes or lymphocytes isolated from mice previously injected with each human melanoma cell line as effector cells and their corresponding human melanoma cells as target cells. Cytotoxic assays were performed at 4 and 16 h; in some assays, effector cells were previously restimulated in vitro with their corresponding target cells. All results were again negative, i.e. human melanoma cells were not recognized by the murine effector cells.
Differences in in vitro proliferation rate, cell cycle distribution and cell cycle gene expression among melanoma cell lines In vitro proliferation rates from 24 to 144 h were compared among the cell lines, using the Alamar Blue assay. At 24 h, the growth rate was slightly higher in Ando-TA2 cells, followed by Ando-2 melanoma cells and Ando-Nude cells (Figure 4) . At 48 h, the growth rate was highly similar between Ando-2 and Ando-Nude cells and slightly higher in Ando-TA2 cells (Figure 4) . At 72 h, however, the proliferation rate was higher in Ando-Nude melanoma cells than in the other two cell lines, which did not differ between them. At 96 and 144 h, Ando-Nude cells showed an even higher value, followed by Ando-2 and Ando-TA2 melanoma cells (Figure 4) . Results for Ando-Tmock and Ando-2 cells were the same in all assays (Figure 4) . The data obtained for Ando-Nude, Ando-Nude-TA2 and Ando-Nude-Tmock cells were also practically identical (data not shown). Comparison of results obtained using Alamar Blue technique and 3-(4,5-dimethylthiazole-2-yl)-2,5-bdiphenyl tetrazolium bromide assay confirmed the validity of our findings (data not shown). These assays were repeated with at least three additional clones or batches of each cell line and the results obtained were always the same.
Exponentially growing tumor cells were plated and the cell cycle distribution was measured at 72-96 h post-incubation. Transfection of HLA-A2 gene in Ando-2 melanoma cells promoted cell arrest in G 0 -G 1 phase. In comparison to Ando-2, Ando-TA2 melanoma cells showed a significant increase (50-60%) in the number of cells in the G 1 phase with a concomitant decrease (27-17%) in the number of cells in the S phase (Table II) . In contrast, Ando-Nude cells showing a significant increase (27-40%) in the number of cells in S phase accompanied by a decrease (50-39%) in the number of cells in G 1 phase (Table II) . Values in Ando-2 and Ando-Tmock cells were practically identical (data not shown). There were no significant differences in the percentage of apoptotic cells (sub-G 0 phase) among the different Ando variants.
Complementary DNA microarray studies showed that the overall gene expression profile was highly similar among these melanoma cell lines, with few differentially expressed genes. Table I lists the differentially expressed genes selected for further verification and quantification by real-time reverse transcription-PCR, along with the primers and conditions used. Data were normalized by using TATA-binding protein and Gliceraldehyde-3-phospate dehidrogenase as housekeeping genes. Figure 5 depicts the real-time reverse transcription-PCR results, using the values for Ando-2 cells as reference (relative value of 1). Cyclin D2 was not expressed by these melanoma cell lines. Three genes were differentially expressed among all three melanoma cell lines: expression of AP-2a in Ando-TA2 cells was 4.5-fold higher than in Ando-2 cells and 7.5-fold higher than in AndoNude cells ( Figure 5) ; expression of cyclin A1 in Ando-TA2 cells was 2-fold higher than in Ando-2 cells and 4-fold higher than in AndoNude cells and expression of p21WAF1/CIP1 in Ando-TA2 cells was 1.8-fold higher than in Ando-2 cells and 3-fold higher than in AndoNude cells ( Figure 5 ). The expression of some other genes was higher in one cell line than in the other two: expression of Mdm2 gene was 2-fold higher in Ando-TA2 cells than in the other two melanoma cell lines and expressions of Cdk2, Cdc25A and E2F1 were around 3-, 2-and 2-fold higher, respectively, in Ando-Nude cells than in the other two melanoma cell lines ( Figure 5 ). The results for Ando-2 and AndoTmock cells were again practically identical ( Figure 5 ). In these assays, Ando-Nude melanoma cells and their corresponding transfected cells presented practically identical results. All these assays were repeated with at least three additional clones or batches of each cell line, always finding the same results.
In vitro migratory and invasive capacities increase with lower MHC-I expression on the melanoma cell lines The melanoma cell lines were allowed to migrate or invade through a Matrigel matrix, using fetal bovine serum-supplemented medium as the chemoattractant. In these migration assays, MHC-I expression was inversely correlated with an increase in the migratory properties of the cell lines (Figure 6a and b) . In the first assay, we compared the migratory capacity by incubating 25 000 cells for 16 h and found significant differences among cell lines. The migratory capacity of Ando-Nude melanoma cells was 5.7-fold higher versus Ando-2 cells and 12.8-fold versus Ando-TA2 cells (Figure 6a ). In the second assay, Ando-2 and Ando-TA2 cells were incubated for 40 h, and a 4-fold higher migratory capacity was found for Ando-2 than for Ando-TA2 cells (Figure 6b) . In both assays, results were practically identical between mock-transfected and Ando-2 cells (Figure 6a and b) .
Ando-Nude cells showed a higher invasive capacity versus the other cell lines, and the difference was even greater than for the migratory capacity (Figure 6c and d) . In the 16 h invasion assay, the invasion capacity of Ando-Nude cells was 23-fold higher versus Ando-2 cells and 50-fold higher versus Ando-TA2 cells (Figure 6c ). In the 40 h assay, the invasion capacity of Ando-2 cells was 7.5-fold higher versus Ando-TA2 cells (Figure 6d) . In both assays, results were practically identical between mock-transfected and Ando-2 cells (Figure 6c and d) . In brief, Ando-Nude cells presented the highest in vitro migratory and invasive capacities and Ando-TA2 cells the lowest ( Figure 6 ). To rule out the possibility that the differences observed were due to variations in proliferation among the melanoma cell lines, the assays were repeated and cells counted after the incubation period. In the 16 h assay, the cell number was very similar among all melanoma cell lines, although slightly higher for Ando-TA2 cells, whereas in the 40 h assay, the cell number was practically identical among all three melanoma cell lines (results similar to those in Figure 4 ). In the migration and invasion assays, Ando-Nude melanoma cells and their corresponding transfected cells presented practically identical results. Again, all assays were repeated using at least three more different clones or batches of each cell line, finding the same results.
Discussion
The present data indicate that defects in MHC-I expression on human melanoma cells endowed them with a double advantage for tumor progression. First, Ando-2 melanoma cells presented loss of one HLA haplotype during tumor progression in the patient, evading the immune system, finding specific CTLps against Ando-TA2 melanoma Table II Data are mean ± SD of at least three experiments performed. Ã P , 0.01 compared with Ando-2 data. (Table I ). Expression level of the genes of interest was determined relative to levels of TATA-binding protein and Gliceraldehyde-3-phospate dehidrogenase housekeeping genes. Ando-2 cells are set to 1. Values are depicted as mean ± SD of three independent experiments performed in quadruplicate. Statistically significant differences in % proliferation observed between Ando-2 tumor cells and Ando-TA2 or Ando-Nude cells (Student's t-test; Ã P , 0.01). MHC-I molecules act as tumor suppressor genes cells in the patient's peripheral blood, i.e. Ando-2 cells transfected with HLA-A Ã 0201 allele (one of the lost alleles). It was previously reported in similar in vitro assays that HLA haplotype loss in lung cancer cells allows them to escape from immune attack (22, 23) . Moreover, Ando-2 melanoma cells may enter a new stage of interaction with the immune system, the immunoblindness phase, where they may not be recognized by the immune system (17) . No specific CTLps against Ando-2 melanoma cells were detected in the blood of our patient. An additional HLA defect (total loss of HLA class I surface expression) was found after growth in immunodeficient mice in the absence of an autologous immune response. Our group previously reported that alterations in HLA class I expression are frequent and reproducible in human melanoma cells grown in immunodeficient mice (17) . Here, we demonstrate that melanoma cells with total HLA class I downregulation (Ando-Nude cells) are more oncogenic per se and have higher in vivo tumorigenicity, proliferation rate and migratory and invasive potentials. Ando-TA2 cells (Ando-2 melanoma cells transfected with HLA-A2 allele, one of the lost HLA alleles) showed the lowest in vivo tumorigenicity and the lowest in vitro proliferation rate and migratory and invasive capacities. According to these in vitro and in vivo findings, the order of direct oncogenic potential of these melanoma cells, which derive from the same cell line, is: Ando-Nude . Ando-2 . Ando-TA2. The present findings demonstrate an inverse correlation between HLA class I expression and these intrinsic oncogenic characteristics in this tumor system.
Hence, HLA class I losses may play an additional role in malignant progression besides immune system escape. MHC-I surface expression defects in murine cells were recently reported to be responsible for resistance to multiple apoptotic stimuli through elevated endoplasmic reticulum stress and defective p53 activation, conferring cell survival advantage (24) . Metastatic cells derived from a single murine fibrosarcoma tumor clone were previously found to present total loss of MHC-I expression in immunocompetent mice and high MHC-I surface expression in immunodeficient mice. Metastatic cell lines without MHC-I expression showed higher in vivo local growth and metastatic potential in immunodeficient mice, whereas metastatic cell lines with high MHC-I surface expression were less oncogenic (13, 25) . Furthermore, MHC-I alterations in B16 murine melanoma cells impaired insulin receptor-regulated signal transduction and augmented resistance to apoptosis (26) . In human studies, these relationships have been reported in neoplastic lymphoid cells but not in normal cells, with HLA molecules mediating programmed tumor cell death in the former when engaged by specific monoclonal antibodies (27) (28) (29) (30) . All these findings strongly suggest that major histocompatibility complex (MHC) molecules may play a role in the regulation of tumor survival and progression, acting directly as tumor suppressor genes.
The expression pattern of three tumor suppressor genes, AP-2a, p21WAP1/CIP1 and cyclin A1 was similar in the three melanoma cell lines, with a higher expression in Ando-TA2 cells and lower in AndoNude cells. Interestingly, the two first genes are located in chromosome 6 (regions 6p24 and 6p21, respectively) very close to the HLA region in 6p21, where HLA heavy chains and the majority of APM genes are located. In many other species, P21WAF1/CIP1 gene is located in the middle of MHC region. Hence, all these genes may share a common regulatory mechanism, and this possibility is supported by the transcriptional downregulation of all these genes in Ando-Nude cells and their transcriptional induction in Ando-TA2 melanoma cells. Furthermore, the loss of HLA class I haplotype in tumor cells, e.g. in Ando-2 melanoma cells, always coincides with the loss of one allele of p21WAP1/CIP1 and one allele of AP-2a. AP-2a gene showed the greatest differences in transcriptional expression among the cell lines under study. Loss of AP-2a expression has been widely implicated in melanoma progression toward a malignant, invasive and metastatic phenotype (31, 32) . The high induction of AP-2a transcriptional expression in Ando-TA2-transfected cells might indicate that the expression of this gene is indirectly regulated by HLA class I molecules. In a metastatic murine model developed in our laboratory, AP-2a gene was upregulated in the MHC-positive metastases from a fibrosarcoma tumor clone but downregulated in the MHC-negative metastases from the same clone (13,25) (I.Romero and A.M.Garcia-Lora, unpublished results). The expression pattern of p21WAF1/CIP1 was broadly similar to that of AP-2a. Regulation of p21WAF1/CIP1 is mainly at transcriptional level and may be independent of p53 (33, 34) , although it may be coregulated with AP-2a gene (35, 36) , which is highly upregulated in Ando-TA2 and downregulated in Ando-Nude melanoma cells. It has been demonstrated that p21WAF1/CIP1 upregulation stops proliferation and promotes senescence, whereas its downregulation is frequently associated with tumor progression and higher invasiveness (37) (38) (39) .
Another gene that may be implicated is cyclin A1, which was 2-and 4-fold lower, respectively, in Ando-2 and Ando-Nude melanoma cells versus Ando-TA2 cells. Cyclin A1 may act as a tumor suppressor gene, given that downregulation of its expression has been reported in various cancers and associated with an invasive phenotype (40) (41) (42) . The upregulation of AP-2a, p21WAF1/CIP1 and cyclin A1 in Ando-TA2 cells may be responsible for their lesser oncogenicity, migration and invasion and for the regression of these tumors in immunodeficient mice, in which hypoxia and nutrient deprivation prevail. Conversely, the downregulation of these genes in Ando-Nude melanoma cells may enhance their oncogenicity. The expression pattern of other cell cycle genes differed among the three melanoma cell lines. For instance, the expression of Mdm2 gene, associated with a reduced invasion capacity (43) (44) (45) , was upregulated in Ando-TA2 cells, whereas the expression of E2F1, Cdk2 and Cdc25A genes, implicated in the transition from G 1 to S phase, suppression of cellular senescence (46, 47) and melanoma progression (48, 49) , was upregulated in Ando-Nude cells. All these results, together with data published by Sabapathy and Nam (24) , suggest a direct connection between MHC-I molecules and cell cycle gene expression.
Loss of MHC-I expression, frequent in cancer cells, is known to play a role in tumor escape from immune system. This study provides evidence that MHC-I defects may also play a direct role in cancer progression, increasing the growth, intrinsic oncogenicity and migratory and invasive potential of cancer cells. These new data on the role of MHC-I molecules in tumor survival and progression suggest their direct action as tumor suppressor genes. Future research efforts should focus on the restoration of MHC-I expression in tumor cells of different histological origin, examining its influence on immune recognition and on the intrinsic oncogenic characteristics of tumor cells, which are of major clinical relevance. Analysis of MHC-I surface expression of a tumor may prove of value to predict its clinical progression and to establish the most appropriate therapeutic approach in each case.
Supplementary material
Supplementary Materials and methods can be found at http:// carcin.oxfordjournals.org/. 
